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Abstract: Acyclovir is not a good candidate for passive permeation since its polarity and
solubility limit is partitioning into the stratum corneum. This work aims to develop a new topical
formulation for the acyclovir delivery. New chitosan nanospheres (NS) were prepared by a modified
nano-emulsion template method. Chitosan NS were characterized by Dynamic Light Scattering (DLS),
Transmission Electron Microscopy (TEM), and an in vitro release study. The in vitro skin permeation
experiment was carried out using Franz cells and was equipped with porcine skin. Biological studies
were performed on the Vero cell line infected by HSV-1 and HSV-2 strains. The acyclovir loaded
chitosan NS appeared with a spherical shape, a size of about 200 nm, and a negative zeta potential
of about 40.0 mV. The loading capacity of the drug was about 8.5%. In vitro release demonstrated
that the percentage of acyclovir delivered from the nanospheres was approximately 30% after six
hours. The in vitro skin permeation studies confirmed an improved amount of permeated acyclovir.
The acyclovir-NS complex displayed a higher antiviral activity than that of free acyclovir against both
the HSV-1 and the HSV-2 strain. The acyclovir-loaded NS showed no anti-proliferative activity and
no signs of cytotoxicity induced by NS was detected. Confocal laser scanning microscopy confirmed
that the NS are taken up by the cells.
Keywords: acyclovir; chitosan nanospheres; antiviral activity; topical infections
1. Introduction
Herpesviruses are responsible for chronic, life-long viral infections that range from asymptomatic
infections or mild cutaneous and mucocutaneous lesions up to severe clinical manifestations as
encephalitis and aseptic meningitis mainly in immunocompromised individuals and newborns [1].
After the primary infection of the skin or mucosa, viruses establish latency into root ganglia and may
intermittently reactivate causing recurrent episodes with or without clinical signs. Herpes Simplex
Virus Type 1 (HSV-1) is a highly contagious virus and is primarily transmitted by oral–oral contact,
which is common and endemic throughout the world. An estimated 3.7 billion people under the age
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of 50 have had an HSV-1 infection [2]. HSV-1 primary infections generally occur during childhood as
asymptomatic infections or as herpetic gingivostomatitis conditions while recurrent manifestations
appear as orolabial lesions, which are called cold sores, fever blisters, or generally herpes labialis.
On the other hand, HSV-2, which is mainly sexually transmitted, is responsible for genital herpes,
which affected an estimated 417 million people worldwide in 2012 [1,2]. Furthermore, the HSV-2
infection increases the risk of acquiring an HIV infection by approximately three-fold and genital
herpes can occur in 60–90% of HIV-infected people [3]. In developed countries, initial genital herpes
episodes caused by HSV-1 are increasing especially among young people [4].
Different anti-herpetic drugs such as acyclovir, famciclovir, and valacyclovir are approved and
used to treat acute symptomatic herpetic infections. These drugs reduce the severity and frequency
of symptoms, but they cannot cure and eradicate the latent infections. Recommendations for the
treatment of genital herpes suggest the use of systemic antiviral drugs, which are orally administered,
to control the signs and symptoms of first clinical and recurrent genital episodes [5]. On the other hand,
treatment of recurrent orolabial mucocutaneous herpes is commonly based on topical antiviral agents
in order to speed up healing of the sores and decrease symptoms such as tingling, pain, burning, and
itching [6]. Acyclovir (9-[(2-hydroxyethoxy)methyl])-9H-guanine), which is a synthetic nucleoside
analogue derived from guanosine, is the drug of choice for treating HSV infections. However, due
to its short half-life and incomplete absorption, it must be taken repeatedly throughout the day to
be effective. Its oral dosage form requires five administrations daily (up to 1200 mg/day) and the
dosage interval for intravenous formulations is eight hours [7]. To overcome this limitation some
derivatives of acyclovir have been developed. For example, valacyclovir, the L-valyl ester of acyclovir,
which displays higher oral bioavailability (30–50%), requires gram doses to be administered orally
(1000 mg three times a day) in order to treat a local infection [8].
In local therapy, acyclovir is not a good candidate for passive permeation since its polarity
(log D =−1.76 at pH 7) and its sparingly solubility in both aqueous and lipid media limit its partitioning
into the stratum corneum. For these reasons, a high frequency of topical application is required.
The cream should be applied about five times a day (every three to four hours) for 4 consecutive days
for cold sores [6].
In this context, an efficient topical acyclovir delivery is highly desirable because it enables targeted
therapy, reduces circulating drug levels, and attenuates the risk of renal insufficiency. Most clinical
studies have shown that the current topical formulations of acyclovir used against herpes labialis
are unable to reach the basal epidermis target site where the virus is found, which results in delayed
antiviral activity and sub-inhibitory concentrations in the basal epidermis, which translate into poor
clinical efficacy [9]. The present work aims to develop a successful new topical formulation for the
delivery of acyclovir that is able to increase the efficacy of the currently available commercial products
for the topical treatment of Herpes simplex virus infections. Additionally, topical administration is
the favored route for local delivery of therapeutic agents due to its convenience, patient compliance,
and affordability. The specific challenge of designing a therapeutic system is to achieve an optimal local
concentration of a certain drug for an appropriate duration of time. In the last decade, more research
focused its attention on topical drug delivery approaches that exploit nanoscale systems to obtain a
sustained release and maintain a localized prolonged therapeutic effect [10]. The nanotechnology-based
strategy might be challenging for the treatment of skin problems that are difficult to address such as
infectious diseases.
The use of nanodelivery systems, either lipophilic or hydrophilic, to improve the percutaneous
absorption of acyclovir has been previously described. Solid Lipid Nanoparticles (SLN) tuned to
incorporate acyclovir improved the dermal delivery in the rat skin model, which suggests their use for
the treatment of Herpes Simplex topical infections [11]. Carboxylated nanosponges have been designed
to improve the acyclovir loading in the nano-carrier and the drug’s effectiveness. A remarkable in vitro
antiviral efficacy was observed when acyclovir was encapsulated within the nanocarrier structure [12].
Al-Subaie et al. designed a nano-emulsion containing a permeation enhancer and dispersed it in a
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chitosan gel for topical application. This formulation showed a two-fold higher drug permeation than
the control in ex-vivo studies [13].
The goal of this work was to prepare chitosan nanospheres (NS) by a purposely modified
nano-emulsion templating method [14] to increase the local acyclovir concentration and favor the local
drug accumulation. The use of natural materials was taken into consideration due to the enormous
interest they have gained as biomaterials for human healthcare systems [15]. Chitosan, a natural
linear polycationic polysaccharide, consists of glucosamine and N-acetylglucosamine monomers
linked through β (1-4) glycosidic linkages and is structurally similar to glycosaminoglycan (GAG)
and its analogs. Due to its biocompatibility, low toxicity, and biodegradability, chitosan is
considered a Generally Recognized as Safe (GRAS) component and its chloride salt is reported
in a monograph of the European Pharmacopoeia. It is of significant interest for industrial and
biomedical applications because it is a cheap, abundant waste product of the food industry with
excellent biocompatibility, degradability, and unique structural and physicochemical characteristics.
Based on these premises, chitosan is an interesting biomaterial for a number of pharmaceutical and
cosmetic applications [16]. Furthermore, chitosan is involved in wound healing and regeneration
processes [17,18]. Moreover, acyclovir permeation through porcine skin after topical application of
loaded NS dispersed in a gel was determined using static Franz cells. Biological assays were carried
out to assess the in vitro antiviral activity of acyclovir-loaded NS against HSV-1 and HSV-2 and their
effect on cell viability.
2. Materials and Methods
2.1. Materials
Acyclovir, chitosan (medium MW, deacetylation 75–85%), fluoresceine isothiocianate, Tween 80,
and Arlacel 83 were purchased from Sigma (Milano, Italy). Solvents and reagents, unless otherwise
indicated, were analytical-grade commercial products and used as received.
2.2. Preparation of Acyclovir-Loaded Chitosan Nanospheres
The preparation method exploits a nano-emulsion as a template in order to obtain nano-sized
particles starting from nano-sized emulsion droplets. A purposely-tuned W/O nano-emulsion was
prepared and then the reduction of the droplet size was obtained by sonication (Sonicator Ultrasonic
Processor XL2020, Misonix Incorporated, 1938, New Highway, Farmingdale, NY, USA), frequency
20 MHz). The nano-emulsion components were FDA-accepted excipients. The external phase consisted
of a mixture of mineral oil and dodecanol (1:1, v/v) while the internal phase was a chitosan acetic acid
solution (1% w/w). Tween 80 (0.50%) and Arlacel 83 (3.25%) were used as surfactants. To obtain the
nanospheres, the nano-emulsion was dropped by a syringe using a roller pump in a sodium citrate
aqueous solution (0.1 M) under stirring. This semi-automatic technique ensures more reproducibility
for the preparation process, which was previously reported [19]. After completing the drift phase,
the system was centrifuged and washed three times with water. Finally, the aqueous suspension of
nanoparticles was filtered.
In order to incorporate the drug in the nanospheres, a series of preliminary experiments were
carried out. These experiments aimed at optimizing the drug amount and the stability of the system.
The tuned acyclovir-loaded chitosan nanospheres were obtained with the same procedure in the
presence of the drug (10 mg/mL) in the internal aqueous phase.
A volume of NS aqueous nano-suspension was freeze-dried using a Modulyo Freeze-dryer
(Edwards, Crawley, UK)) to obtain a solid powder.
2.3. Preparation of Fluorescent-Labelled Chitosan Nanospheres
Fluorescent chitosan NS were obtained by labeling freeze-dried pre-formed chitosan NS with
fluorescein isothiocyanate (FITC), which was previously reported. For this purpose, an FITC
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dimethylsulfoxide solution (10 mg/mL) was added to the chitosan nanosphere suspension under
stirring for 24 h at room temperature in the dark. At the end of the labeling procedure, an aliquote of
NS aqueous nano-suspension was freeze-dried using a Modulyo Freeze-dryer (Edwards, Crawley, UK)
to obtain a solid powder.
2.4. Characterization of Acyclovir-Loaded Nanospheres
Average particle diameter, polydispersity index, and Z potential of the acyclovir-loaded NS,
fluorescent-labelled NS, and blank NS were determined by Photon Correlation Spectroscopy using
a 90 Plus particle sizer (Brookhaven Instruments Corporation, Holtsville, NY, USA), equipped with MAS
OPTION particle sizing software (Brookhaven Instruments Corporation). The measurements were made
at a fixed angle of 90◦ for all samples, which were suitably diluted with filtered distilled water for every
measurement. Zeta potential measurements were also made using an additional electrode in the same
instrument. For zeta potential determination, samples of the three formulations were diluted with 0.1 mM
KCl and placed in the electrophoretic cell in which an electric field of about 15 V/cm was applied.
2.5. Morphology Determination
The morphology of the acyclovir-loaded NS was observed by Trasmission Electron Microscopy
(TEM). Transmission electron microscopy (TEM) was employed to evaluate the particle shape and
morphology. Philips CM 10 transmission electron microscope (Philips Electron Optics, Eindhoven,
the Netherlands) was used and the particle size was measured using the NIH image software
(NIH, Bethesda, MD, USA). The nanosponge suspensions were sprayed on Formwar-coated copper
grid and air-dried before observation.
2.6. Quantitative Determination of Acyclovir
The quantitative determination of acyclovir was carried out by HPLC analysis using a
Perkin Elmer instrument (L2 Binary Pump, Perkin Elmer, Waltham, MA, USA) with a UV-vis
spectrophotometer detector (LC 95, Perkin Elmer). A reverse-phase hypersil octadecyl-silica (ODS)
column (25 cm × 4.6 mm Varian, Agilent Technologies, Santa Clara, CA, USA) was used with a mobile
phase consisting of a 12:88 (v/v) ratio of acetonitrile: 20 mM ammonium acetate buffer pH = 3.5 and a
flow rate of 1 mL/min. The UV detector wavelength was set to 250 nm. The acyclovir concentration
was calculated using an external standard method from a standard calibration curve. The acyclovir
calibration curve was linear in the range 0.5–15 µg/mL with r2 of 0.9997.
2.7. Determination of Acyclovir Encapsulation Efficiency and Loading Capacity
The loading capacity was determined from freeze-dried loaded samples. A weighted amount
of freeze-dried acyclovir-loaded NS (about 3 mg) was dispersed in 5 mL of distilled water at a pH
equal to 2.3 and adjusted by HCl. After sonication for 15 min and centrifugation at 5000 rpm for
20 min, the supernatant was analyzed by HPLC for the quantitative determination of acyclovir.
The encapsulation efficiency and loading capacity of acyclovir-loaded chitosan NS were calculated
using the equations below.
Encapsulation efficiency % =
Amount of acyclovir in NS
Weight of acyclovir
× 100 (1)
Loading capacity % =
Amount of acyclovir
Weight of acyclovir− loaded NS × 100 (2)
2.8. Thermal Analysis
Differential Scanning Calorimetry (DSC) was carried out by means of a Perkin Elmer DSC/7
differential scanning calorimeter (Perkin-Elmer, Waltham, MA, USA) equipped with a TAC 7/DX
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instrument controller (Perkin-Elmer). The instrument was calibrated with indium for melting point
and heat of fusion. A heating rate of 10 ◦C/min was employed in the 25–300 ◦C temperature range.
The standard aluminum sample pans (Perkin-Elmer) were used. An empty pan was used as a
reference standard. Analyses were performed in triplicate using about 3 mg freeze-dried samples
under nitrogen purge.
2.9. In Vitro Drug Release Kinetics
The in vitro release kinetics studies were carried out using a multi-compartment rotating disk
composed by several donor cells on one side separated from receiving cells by a hydrophilic dialysis
membrane (Spectra/Pore, Spectrum®, cut-off 12,000–14,000 Da).
The donor phase consisted of 1 mL of acyclovir-loaded NS nanosuspension in PBS solution
(pH 5.5) at a concentration of 5 mg/mL. The receiving phase consisted of PBS solution at pH 5.5. It was
completely withdrawn at fixed times (15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, and 6 h) and replaced
with the same amount of fresh PBS solution. The concentration of acyclovir in the withdrawn samples
was detected by HPLC.
The kinetic release behavior of acyclovir loaded in NS was compared to a free acyclovir phosphate
buffer solution. The experiment was carried out in triplicate.
2.10. In Vitro Permeation Studies
The in vitro acyclovir permeation was studied using vertical static glass Franz cells purposely
equipped with slices of ear pig skin to mimic the stratum corneum properties.
A hydrophilic gel consisting of 1% hydoxyethylcellulose was prepared and subsequently mixed
1:1 with acyclovir-loaded aqueous formulation. The drug permeation through ear pig skin from the
acyclovir-loaded NS gel formulation and from a commercial cream formulation (Aciclovir Mylan
Generics, Mylan S.p.A., Milano, Italy) were evaluated. Skin slices (1 mm thick) were isolated with a
dermatome from the inner side of pig ears and then frozen at −18 ◦C. Before the experiments, the
thawed skin was equilibrated in saline solution (NaCl 0.9% w/w), which had sodium azide (0.01%)
added to preserve the skin at 25 ◦C for 30 min. After washing with saline solution, the skin layer
was inserted between the two compartments of the vertical glass Franz cell with the stratum corneum
side facing towards the donor chamber. The Franz cell was magnetically stirred at 1000 rpm and
maintained at a constant temperature of 32 ± 1 ◦C using jacketed cells and a thermosetting system.
The donor compartment contained 0.5 g of formulation.
The receptor phase consisted of a phosphate saline buffer 0.05 M (pH 5.5). At fixed times,
the receptor phase (5 mL) was completely withdrawn and immediately replaced with an equal volume
of fresh buffer.
The amount of acyclovir accumulated in the skin was quantitatively determined at the end of the
in vitro experiment after skin slice extraction with methanol. Each experiment was repeated three times.
2.11. Biological Assays
2.11.1. Cells
African green monkey kidney cells (Vero) (ATCC CCL-81) were purchased from the American
Type Culture Collection (ATCC; Manassas, VA, USA). The culture medium for cells was Eagle’s minimal
essential medium (MEM) (Gibco/BRL, Gaithersburg, MD, USA) supplemented with heat-inactivated
10% fetal calf serum (FCS) (Gibco/BRL) and 1% antibiotic-antimycotic solution (Zell Shield, Minerva
Biolabs GmbH, Berlin, Germany).
2.11.2. Viruses
The neurovirulent strains LV [20] and MS (American Type Culture Collection cat. no. VR-540)
of HSV-1 and HSV-2, respectively, were used for in vitro experiments. Both strains were sensitive to
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acyclovir. Viral stocks were generated as previously described by Donalisio and collaborators [21].
Both strains were titrated by plaque assay on Vero cells.
2.11.3. Cell Viability Assay
Vero cells were cultured in 96-well plates and incubated with acyclovir, acyclovir-loaded NS,
and only NS at different concentrations and in triplicate. Cells were cultured under the same
experimental conditions used for the in vitro antiviral assays and viability was determined by the
CellTiter 96 Proliferation Assay Kit (Promega, Madison, WI, USA) according to the manufacturer’s
instructions. Absorbances were measured using a Microplate Reader (Model 680, BIORAD, Hercules,
CA, USA) at 490 nm. The effect on cell viability of NS at different concentrations was expressed as a
percentage by comparing absorbances of treated cells with cells incubated with culture medium alone.
The 50% cytotoxic concentrations (CC50s) and 95% confidence intervals (CIs) were determined using
Prism software (Graph-Pad Software, San Diego, CA, USA).
2.11.4. Cytotoxicity Assay
The cytotoxic effect of acyclovir, acyclovir-loaded NS, and only NS on Vero cells was measured by
analyzing the release of lactate dehydrogenase (LDH) in the culture medium of treated cells. According
to the manufacturer’s protocol of the LDH Cytotoxicity Detection Kit (TAKARA Bio Inc., Kusatsu,
Japan), the lactate dehydrogenase release into the cell culture supernatant is directly proportional to
the accumulation of dead cells [22].
2.11.5. Virus Yield Reduction Assay
Vero cells were seeded in 24-well plates at a density of 10× 104 cells. After 24 h, cells were infected
in duplicate with HSV-1 or HSV-2 at a multiplicity of infection (MOI) in 0.01 plaque-forming units
(PFU)/cell. Following virus adsorption (2 h at 37 ◦C), the virus inoculum was removed and cells were
washed and exposed to acyclovir or acyclovir-loaded NS until untreated cultures displayed extensive
cytopathology. Supernatants were harvested and cell-free virus infectivity titers were determined in
duplicate by the plaque assay in Vero cell monolayers. The end-points of the assay were the inhibitory
concentrations that reduced the virus yield by 50% (IC50) versus the untreated virus control. The IC50
values for inhibition curves were calculated by using the program PRISM 4 (GraphPad Software,
San Diego, CA, USA) to fit a variable slope-sigmoidal dose–response curve. A selectivity index (SI)
was calculated by dividing the CC50 by the IC50 value.
2.11.6. Evaluation of Cellular Uptake by the Confocal Laser Scanning Microscopy
Exponentially growing Vero cells were plated and cultured overnight in 24-well plates on glass
coverslips. Subsequently, the cell monolayers were incubated with 100 µM of the labeled NS for the
indicated time points and then extensively washed with PBS for the observation of the living cells.
Confocal sections were taken on an inverted Zeiss LSM510 fluorescence microscope (Zeiss, Jena, Germany).
2.11.7. Statistical Analysis
The results are expressed as mean ± SD. Statistical analyses were performed using an unpaired
Student’s t-test. A value of p < 0.05 was considered significant.
3. Results and Discussion
In this research, chitosan nanospheres were designed as delivery systems for acyclovir topical
administration. Chitosan-based nanocarriers have been widely studied for the unique properties of
this polymer and, in particular, for its capability to interact with various epithelia and muco-adhesion
properties. Several past studies referred to chitosan-based nanocarriers for skin and mucosal drug
delivery [23–25].
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Chitosan has been exploited for the delivery of acyclovir by Hasanovic et al. who developed
chitosan-tripolyphosphate nanoparticles to enhance the chemical stability of the drug [24].
Chitosan nanospheres with enhanced characteristic were prepared by combining a previous tuned
method based on ionic gelation [19] and the nano-emulsion templating method [26]. This peculiar
experimental set-up permitted to obtain stable chitosan nanospheres is able to load acyclovir to a great
extent. As already reported, this innovative preparation procedure has been tailored to guarantee high
reproducibility in the formulation process, which reduces manual mistakes.
The average diameter, polydispersity index, zeta potential, encapsulation efficiency, and loading
capacity values of the three types of NS formulations (loaded, blank, and fluorescent) are reported
in Table 1.
Table 1. Summary of the physico-chemical characterization of Acyclovir-loaded chitosan nanospheres
(NS), blank NS, and fluorescent NS. PDI: Polydispersity Index; ZP: Zeta Potential.
Parameters Acyclovir NS Blank NS Fluorescent NS
Average diameter ± SD (nm) 200.0 ± 5.0 205.0 ± 5.2 285.0 ± 4.9
Polydispersity Index(PDI) 0.10 0.10 0.12
Zeta Potential (ZP) ± SD (mV) 40.6 ± 10.6 38.6 ± 16.5 38.6 ± 16.5
Encapsulation efficiency (%) 86 ± 1.45
Loading capacity (%) 8.5
The drug loading of acyclovir was found to be (8.5%) with an encapsulation efficiency of about
87%. This result further confirmed the success of the proposed experimental set up and allowed an
enhancement of the drug loading amount in comparison to previous investigations [24].
DSC analysis showed that the drug is molecularly dispersed in the polymer matrix due to the
complete disappearance of the melting endotherm peak at 255 ◦C of acyclovir, which suggests a
complete amorphization of the drug in the carrier (Data not shown).
The TEM micrograph of the acyclovir loaded NS is reported in Figure 1. It shows that nanoparticles
have a spherical shape and nearly smooth surface structures. TEM analysis also revealed that
acyclovir-loaded chitosan NS are discrete and non-aggregated.
Figure 1. Transmission electron microscopy (TEM) image of acyclovir-loaded chitosan nanoparticles.
The In vitro release study (Figure 2) showed a prolonged release kinetics of acyclovir-loaded NS
compared to the free acyclovir aqueous solution. After 3 h, about 20% of acyclovir was released from
chitosan NS.
The in-vitro permeation studies were performed comparing the acyclovir-loaded NS gel formulation
and a commercial cream formulation for 24 h. Figure 3 displays the percentage of the permeated acyclovir
through the porcine skin after 1 h and after 24 h of administering the semisolid formulations. The results
confirmed the enhancement of acyclovir permeation through the skin when delivered by the chitosan
NS gel. In fact, after 1 h, a significant difference between the amount of acyclovir permeated after the
release from the commercial cream and from the chitosan NS gel was observed. In the former case,
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about 0.1% of the drug permeated through the porcine skin while in the latter this value was up to 0.4%.
The same trend was confirmed after 24 h when the acyclovir released from the chitosan NS gel was
at about 55%, which is remarkably higher than the 10% that permeated from the commercial cream.
The amount of acyclovir accumulated in the skin was quantitatively determined at the end of the in vitro
experiment after the skin slice extraction method using methanol. The quantitative analysis showed that
the acyclovir accumulation in the pig skin was about 1% for the drug commercial formulation and about
30% for the acyclovir released from the chitosan NS gel after 24 h.
Figure 2. In vitro release kinetics of acyclovir from the drug aqueous solution and from the chitosan
acyclovir NS.
Figure 3. Comparison of Acyclovir permeation through porcine skin from the chitosan NS gel and
commercial cream.
As far the biological results are concerned, virus yield reduction assays were performed to
compare the antiviral activity of plain acyclovir and acyclovir-loaded NS against HSV-1 and HSV-2
infections. Both viruses were sensitive to acyclovir. This antiviral assay evaluates the production of
infectious viruses after multiple cycles of viral replication. The assay was performed on monolayers
of Vero cells incubating serial dilutions of tested formulation after viral adsorption. As shown by
the dose-response curves in Figure 4, the acyclovir-NS complex displayed higher antiviral activity
than the activity of free acyclovir against both HSV-1 and HSV-2 infections. In particular, IC50 values
against HSV-1 determined at 48 h post infection were found to be 0.012 µM (95% CI: 0.011–0.014)
for acyclovir-loaded NS and 0.156 µM (95% CI: 0.123–0.197 µM) for free acyclovir while those
obtained against HSV-2 determined at 24 h post-infection were 0.100 µM (95% CI: 0.081–0.124 µM)
for acyclovir-loaded NS and 1.608 µM (95% CI: 1.255–2.060 µM) for free acyclovir. Virus titers were
determined at 48 h or 24 h post-infection for HSV-1 or HSV-2 respectively due to the different replication
time of the two viruses. The IC50 values for plain acyclovir are consistent with previously published
values [27,28]. No antiviral activity was exerted by the unloaded NS at tested doses (see Figure 4).
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Figure 4. Antiviral activity of free acyclovir, acyclovir-loaded NS, and plain carrier (NS) against HSV-1
(A) and HSV-2 (B). Vero cells were infected at a multiplicity of infection (MOI) of 0.01 and then exposed
to different drug concentrations. Virus titers in the supernatants of cell cultures were determined by a
standard plaque assay at 48 h or 24 h post-infection for HSV-1 or HSV-2, respectively. Values are the
means of three separate determinations.
To exclude that the inhibitory activities observed were due to cellular alterations, a cell viability
assay and a cell cytotoxicity assay were performed on treated Vero cells under the same experimental
conditions used for antiviral assays. As reported in Figure 5, acyclovir-loaded NS did not affect cell
viability at the concentrations and time points chosen. On the other hand, the plain carrier shows a
weak inhibition of cellular proliferation at high doses after 24 h and 48 h post treatment.
Figure 5. Effect of acyclovir, acyclovir-loaded NS, and only NS on the viability of non-infected Vero
cells as a function of the drug concentration at 24 h (A) and 48 h (B). X axis: NS concentration, Y axis:
cell viability (% of untreated control). Each point represents the mean ± SD (n = 3).
The cell cytotoxicity assay was carried out by measuring the level of LDH. A stable cytoplasmic
enzyme that is released into the cell culture supernatant upon damage of the cytoplasmic membrane.
No significant difference in the release of the cytoplasmic enzyme LDH was observed between
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formulations-treated cells and untreated cells, which indicates no signs of cytotoxicity induced by NS
(see Figure 6).
Figure 6. Cytotoxic effect of acyclovir, acyclovir-loaded NS, and NS alone on non-infected Vero cells
by measuring the release of lactate dehydrogenase in culture medium at 24 h (A) and 48 h (B). X axis:
nanospheres concentration, Y axis: release of lactate dehydrogenase (% of untreated control). Each point
represents the mean ± SD (n = 3).
These experiments revealed that the acyclovir-loaded NS are not cytotoxic with CC50 values
(50% cytotoxic concentration) higher than 100 µM and the selectivity index (SI) greater than 7936 or
1000 for HSV-1 and HSV-2, respectively.
In order to investigate whether NS could penetrate inside cells and deliver acyclovir, we examined
Vero cells treated with fluorescent nanoparticles by using a confocal laser scanning microscopy.
The assay was carried out on living unfixed cells to avoid misleading due to the cell fixation
protocols. As shown in Figure 7, virtually all NS were internalized in the cells and localized in the
cytoplasm within 3 h from treatment with a preferential accumulation in the perinuclear compartment.
Other studies on particulate delivery systems described a perinuclear accumulation of nanoparticles
after internalization in cells [29–31]. Fluorescence was not detected in control cells that had not been
exposed to the labeled compounds.
Figure 7. Cell uptake of fluorescent NS. Vero cells were incubated with the formulation for the times
indicated and then analyzed by confocal laser scanning microscopy without fixation. The upper
panels show the fluorescence images while the lower panels show fluorescence images merged with
phase-contrast images. The first column on the left shows the control cells, which were not incubated
with the formulation (NT = no treated).
4. Conclusions
The present work aimed at developing a successful new topical formulation for the delivery
of acyclovir was able to increase the efficacy of the currently available commercial products for
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the topical treatment of Herpes simplex virus infections. For this purpose, chitosan, which is a
natural linear polycationic polysaccharide, was selected due to its biocompatibility, low toxicity, and
biodegradability. Moreover, chitosan is an interesting biomaterial for dermatological applications since
it can play a key role in wound healing and regeneration processes. In this research study, a purposely
modified nano-emulsion templating method was used as an innovative experimental set up to prepare
chitosan nanospheres loaded with acyclovir. In comparison with previous scientific investigations,
the proposed chitosan nanoparticles system showed improved characteristics such as enhanced drug
loading amount, prolonged release kinetics, no cytotoxicity, and an improved in vitro antiviral efficacy.
Moreover, the chitosan nanospheres tuned in this work were successfully able to act as skin surface
reservoir of acyclovir, which enhance its skin permeation in comparison with a commercial topical
formulation. This mechanism of action allows an improved topical delivery of anti-infectives, which
are delivered to the stratum corneum or epidermis and retained there for a prolonged time against
microbials. Furthermore, in vitro biological studies demonstrated a higher antiviral activity of the
acyclovir-loaded chitosan nanospheres than that of free acyclovir against both the HSV-1 and HSV-2
strains. These promising results underline the possibility to increase the efficacy of the currently
available acyclovir topical formulations using this new nano-technological approach.
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